GOTHENBURG, Sweden, Oct. 23, 2025 /PRNewswire/ --

Third quarter

   -- Sales of SEK 835 (867) million, 3% growth in local currencies and a 4% 
      decrease in SEK, due to a significant currency impact of -7%. Organic 
      growth in local currencies excluding discontinued business* was 5%. 
 
   -- Sales per region, in local currencies, were -2% in EMEA, +4% excluding 
      discontinued business, +11% in Americas and +1% in APAC. 
 
   -- Sales per product group, in local currencies excluding discontinued 
      business, were +7 in Consumables, +8% in Technologies and +3% in 
      Genetics. 
 
   -- Sales per product group, in local currencies, were +4% in Consumables, 
      +8% in Technologies and 0% in Genetics. 
 
   -- Gross margin increased to 58.9% (58.6), explained by a favourable product 
      mix despite negative currency impact. 
 
   -- Earnings before depreciation and amortisation (EBITDA) amounted to SEK 
      253 (289) million, resulting in an EBITDA margin of 30.3% (33.4), 
      impacted by negative currency effect. 
 
   -- Operating cash flow amounted to SEK 255 (206) million. 
 
   -- Net income amounted to SEK 102 (116) million, resulting in earnings per 
      share of SEK 0.75 (0.85). 

First nine months

   -- Sales of SEK 2,548 (2,650) million, 1% growth in local currencies and a 
      4% decrease in SEK, due to a significant currency impact of -5%. Organic 
      growth in local currencies excluding discontinued business was 4%. 
 
   -- Sales per region, in local currencies, were +1% in EMEA, +8% excluding 
      discontinued business, +8% in Americas and -5% in APAC. 
 
   -- Sales per product group, in local currencies excluding discontinued 
      business, were +7% in Consumables, -1% in Technologies and +3% in 
      Genetics. 
 
   -- Sales per product group, in local currencies, were +4% in Consumables, 
      -2% in Technologies and +1% in Genetics. 
 
   -- Gross margin decreased to 58.1% (58.6) negatively impacted by currency. 
 
   -- Earnings before depreciation and amortisation (EBITDA) amounted to SEK 
      753 (888) million, resulting in an EBITDA margin of 29.5% (33.5), 
      significantly impacted by negative currency effect. 
 
   -- Operating cash flow amounted to SEK 475 (640) million. 
 
   -- Net income amounted to SEK 301 (375) million, resulting in earnings per 
      share of SEK 2.23 (2.76). 

Gothenburg, October 23, 2025

VITROLIFE AB (publ)

Bronwyn Brophy O'Connor,

CEO

* Discontinued business refers to discontinued activities in certain markets in EMEA.

The information was submitted for publication, through the agency of the contact persons set out above, at 23-10-2025 08:00 CET.

Contact:

Amelie Wilson, Investor relations, external corporate communications and executive support, awilson@vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/vitrolife-ab--publ-/r/interim-report-q3--2025--strong-growth-in-americas, c4254622

The following files are available for download:

 
https://mb.cision.com/Main/1031/4254622/3737742.pdf  Interim report Q3 2025 
 

View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ---interim-report-q3-2025-strong-growth-in-americas-302592532.html

SOURCE Vitrolife AB (publ)

(END) Dow Jones Newswires

October 23, 2025 02:38 ET (06:38 GMT)